The companies will collaborate to streamline and accelerate research workflows in pathology and oncology for higher quality, improved consistency and faster throughput. Leica Biosystems will distribute Paige’s research-use-only (RUO) computational pathology products, starting with Paige Prostate RUO, that identify areas of interest in tumor tissue and help researchers quantify and subtype tissue more efficiently and objectively. This software will be paired with Leica Biosystems digital pathology platform including slide image scanners and image management software. Additional detection efforts will focus on other indications.
“We are excited to partner with Leica Biosystems in our mutual goal to define the future of cancer research through the expanded access of computational pathology products for research,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our proprietary software with the reliability of Leica hardware, we can better serve the research needs of the pathology community as it undergoes a rapid digital transformation.”
“We are very excited about this collaboration with Paige. Our goal is to provide our customers with the tools that they need to continue to advance research and ultimately patient care,” said Christopher Riley, Interim President of Leica Biosystems. “Paige’s AI-powered solutions are central to this effort.”
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI- based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Visit LeicaBiosystems.com for more information.